Skip to main content

Primary Care and HIV: Substance Use Disorder

AAHIVM Course Banner
1.5 CEUs
Primary Care and HIV:
Substance Use Disorder

Module DescriptionThese days, many patients with HIV prefer to see the same medical provider to treat their HIV and Primary Care needs. The Academy's Primary Care and HIV Program highlights special considerations for HIV Specialists treating the Primary Care needs of their patients and informs Primary Care Providers about the unique considerations of people with HIV. The relationship between HIV infection and substance use encompasses all stages–transmission, diagnosis, progression, and treatment and can contribute to increased HIV transmission through needle-sharing and/or impaired judgment.

Credit Dates12/10/2021 – 12/09/2022

Jointly provided by Postgraduate Institue for Medicine and the American Academy of HIV Medicine.

This activity is supported by independent educational grants from Gilead Sciences and Merck & Co. 





Learning Objectives
  • Compare and contrast the epidemiology of substance use disorder (SUD) in the general population to people with HIV
  • Review the criteria for diagnosing substance use disorder in people with HIV
  • Assess the risk factors for substance use disorder in people with HIV
  • Demonstrate appropriate assessment for substance use disorder in people with HIV
  • Apply management strategies for substance use disorder in people with HIV

Target Audience
This activity is intended for physicians, PA’s, NP’s, RN’s, and pharmacists who are engaged in the care of patients with HIV.

Presenter
Michael Fingerhood, MD, FACP, DFASMAM, AAHIVS
Assistant Professor of Medicine and Public Health
Johns Hopkins University
Baltimore, MD

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity.

During the period December 10, 2021 through December 9, 2022, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 16413. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com or visit www.pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the American Academy of HIV Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education Credit The Postgraduate Institute for Medicine designates this internet activity for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education The Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of Accreditation Council for Pharmacy Education (Universal Activity #JA4008162-9999-21-384-H02-P). Type of Credit: Knowledge

Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours, APRN 0.1credits.

Disclosure of Conflict of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty
Dr. Clark has nothing to disclose.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Academy managers have nothing to disclose.

Media: Internet

Computer System Requirements
This program requires the use of an internet-connected computer or device and a modern web browser capable of streaming video.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.